Literature DB >> 6896012

Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity.

E S Kleinerman, L A Zwelling, R Schwartz, A V Muchmore.   

Abstract

We have shown previously that cis-diamminedichloroplatinum(II) (cis-DDP), an active antineoplastic agent, and X-irradiation enhanced human spontaneous monocyte-mediated cytotoxicity in vitro. To ascertain whether this is a unique property of cis-DDP or common to other effective antineoplastic agents, we studied the effect of L-phenylalanine mustard (L-PAM), Adriamycin (ADR), actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) on spontaneous monocyte-mediated cytotoxicity, cis-DDP, ADR, L-PAM, and m-AMSA under appropriate in vitro conditions all increased spontaneous monocyte-mediated cytotoxicity. Activation involved (a) direct monocyte activation (cis-DDP and ADR); (b) inactivation of suppressor lymphocytes (X-irradiation); (c) a combination of the two (L-PAM); or (d) mechanisms not yet elucidated (m-AMSA). In contrast, incubating mononuclear leukocytes with 0.4 microgram actinomycin D per ml depressed monocyte-mediated killing. Thus, while stimulation of "nonspecific" killing is not a unique property of cis-DDP, it is not a universal effect of all chemotherapy agents. The stimulation and enhancement of already existing host defense mechanisms may be an important additional way in which many chemotherapeutic agents exert their antitumor effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896012

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Phenotypic variations dictate the intracellular compartmentalization of doxorubicin in normal human bone marrow cells.

Authors:  E Aghaï; Z A Tökés
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.

Authors:  M Nagarkatti; P S Nagarkatti; A M Kaplan
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth.

Authors:  S Ben-Efraim; R C Bocian; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

5.  Adriamycin induced resistance of sensitive K 562 cells to natural killer lymphocyte attack.

Authors:  H Benoist; C Madoulet; J C Jardillier; A Desplaces
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  The synergistic tumoricidal activity of anticancer drugs and oxidative burst-triggered macrophages.

Authors:  S Marcovitch; Y Keisari
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Effects of low-dose mafosfamid on the lymphokine-activated killer cell activity of peripheral blood mononuclear cells determined by a clonogenic microassay.

Authors:  H R Maurer; C Echarti
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

8.  Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.

Authors:  H Shindo; T Ogura; T Masuno; S Hayashi; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.

Authors:  Pooja Dhupkar; Nancy Gordon; John Stewart; Eugenie S Kleinerman
Journal:  Cancer Med       Date:  2018-05-07       Impact factor: 4.452

10.  Purification and characterization of a mannose-containing disaccharide obtained from human pregnancy urine. A new immunoregulatory saccharide.

Authors:  A V Muchmore; J M Decker; R M Blaese; B Nilsson
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.